Synonyms: compound 21 [PMID: 28287730] | PF-06747775 | PF06747775
Compound class:
Synthetic organic
Comment: Mavelertinib (PF-06747775) is a third generation mutant EGFR receptor tyrosine kinase inhibitor that has potential antineoplastic activity [1]. It is an irreversible inhibitor with selectivity for mutant EGFRs carrying the four common mutants (exon 19 deletion (Del), L858R, and double mutants T790M/L858R and T790M/Del) over wild-type EGFRs.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
A Phase 2 clinical trial of PF-06747775 (alone or in combination with palbociclib or avelumab) in EGFR mutant non-small cell lung cancer (NCT02349633) is underway. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02349633 | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | Phase 2 Interventional | Pfizer |